Eli Lilly shares promising phase 3 results for once-weekly insulin efsitora in type 2 diabetes
It is hoped that a once-weekly treatment option could lead to improved adherence
Stay updated with breaking news from Jeff Emmick. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
It is hoped that a once-weekly treatment option could lead to improved adherence
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the QWINT-2 and QWINT-4 phase 3 clinical trials evaluating...
Eli Lilly announced today the first positive results of two Phase 3 clinical trials evaluating the once-weekly insulin efsitora alfa in adults with type 2 diabetes using insulin for the first time,...
The pharma giant known for its diabetes and weight loss medications shared results of a late-stage clinical trrial for its long-acting insulin